Pyc Therapeutics Limited · ASX:PYC

Pyc Therapeutics — Investor Presentation (September 2019)

12 slides from Pyc Therapeutics's investor presentation, Sep 4, 2019

  1. Slide 1: PYC Therapeutics Investor Relations Presentation September 2019

    For personal use only PYC Therapeutics Investor Relations Presentation September 2019

  2. Slide 2: The delivery challenge: getting big drugs inside cells

    The delivery challenge: getting big drugs inside cells The promise of breakthrough medicine can only be realised once the ‘delivery challenge’ has been solved For personal use only Outside The Opportunity cell The highest value drug targets (DNA, RNA, protein) exist inside Inside cell cells DNA The

  3. Slide 3: PYC Therapeutics solves the delivery challenge with our Cell-Penetrating Peptide (CPP) technology

    PYC Therapeutics solves the delivery challenge with our Cell-Penetrating Peptide (CPP) technology For personal use only PYC Therapeutics’ solution Cell Penetrating Peptides (CPPs) are able to cross the cell Outside membrane – CPPs can be joined to a drug cargo to deliver cell it inside the cell Insi

  4. Slide 4: PYC's delivery platform uses Nature's solution to a complex problem

    PYC’s delivery platform uses Nature’s solution to a complex problem For personal use only Nature has worked out how to cross the cell membrane – viruses and other micro-organisms can enter human cells Outside Outside cell cell Inside cell Inside cell DNA DNA Drug Virus We take the … to make We remov

  5. Slide 5: PYC has a clear competitive advantage in the amount of drug cargo that we can deliver

    PYC has a clear competitive advantage in the amount of drug cargo that we can deliver Our delivery technology delivers 4x as much drug Getting enough drug cargo inside the cell is the rate- For personal use only cargo inside cells than our nearest competitor’s limiting step in the development of pre

  6. Slide 6: PYC drives shareholder returns through two commercial applications of our delivery platform

    PYC drives shareholder returns through two commercial applications of our delivery ‘platform’ For personal use only 1 Development of our own pipeline of drugs PYC’s delivery platform  Develop our own cargoes for our area of + focus, starting with Inherited Retinal Disease PYC’s drug  PYC owns the

  7. Slide 7: Developing our drugs: PYC is targeting significant markets of unmet need

    1 Developing our drugs: PYC is targeting significant markets of unmet need For personal use only Illustrative drug value proposition – Inherited Retinal Disease example Pre- IND- Development stage Discovery Phase 1 Phase 2 Phase 3 Marketing clinical enabling Current progress We are here Potential by

  8. Slide 8: PYC has a clear set of milestones to deliver our lead drug

    1 PYC has a clear set of milestones to deliver our lead drug For personal use only Milestone impacting valuation and progress to market Pre-clinical IND-enabling IND Phase 1 Phase 2 Phase 3 NDA  Proof of  Drug molecule  Investigational  First dosing of  First dosing in combined Phase  New Drug

  9. Slide 9: Licencing out PYC's CPP delivery platform

    2 Licencing out PYC’s CPP delivery platform For personal use only Developmental stage of PYC and Partner’s pipeline in 2020 Program Discovery Pre-clinical Clinical Marketed Ocular Inherited retinal disease #1 Brain Neuro-degenerative disease Liver Genetic liver disease New therapeutic Oncology targe

  10. Slide 10: PYC will be operating in a competitive landscape

    PYC will be operating in a competitive landscape For personal use only Eye disease landscape examples Antisense Oligo landscape examples Geographic base Australia US US Netherlands US Platform or asset Platform Platform Asset Asset Platform Development stage Pre-clinical Clinical (Phase 1) Clinical

  11. Slide 11: The scientific team

    The scientific team For personal use only Scientific Advisory Board Operational Team Rohan Hockings Shohei Koide MBBS (Hons.), JD GDLP B.S, M.S, Ph.D Experience across both Professor of Biologics clinical and commercial roles Design at New York University Kaggen Ausma World-leader in the LLB, B.Econ

  12. Slide 12: Disclaimer

    Disclaimer For personal use only The purpose of this presentation is to provide an update of the business of PYC Therapeutics Limited (ASX:PYC) [‘PYC’]. These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. A

PYC Therapeutics — Investor Presentation (September 2019) on 6ix